GABA A receptor physiology and its relationship to the mechanism of action of the 1,5-Benzodiazepine clobazam

CNS Drugs

Volumn 26, Issue 3, 2012, Pages 229-244

  Sankar, Raman ^a  

^a MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

Antiepileptic drugs; Anxiety; Anxiolytics; Clobazam; Epilepsy; GABA A receptor agonists; Lennox Gastaut syndrome.

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA2; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA5; 4 AMINOBUTYRIC ACID A RECEPTOR BETA3; AMOBARBITAL; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; BUSPIRONE; CHLORDIAZEPOXIDE; CLOBAZAM; CLONAZEPAM; CLORAZEPATE; CYTOCHROME P450; DIAZEPAM; DRUG METABOLITE; ESTAZOLAM; FLURAZEPAM; LORAZEPAM; MIDAZOLAM; NITRAZEPAM; NORCLOBAZAM; OXAZEPAM; PRAZEPAM; RECEPTOR SUBTYPE; RECOMBINANT RECEPTOR; TEMAZEPAM; TRIAZOLAM;

ALLOSTERISM; AMNESIA; ANTICONVULSANT ACTIVITY; ANXIETY DISORDER; ATAXIA; CENTRAL NERVOUS SYSTEM; COGNITION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; EPILEPSY; FOOD AND DRUG ADMINISTRATION; GABAERGIC SYSTEM; HUMAN; LEARNING; LENNOX GASTAUT SYNDROME; MEMORY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR UPREGULATION; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; TRANQUILIZING ACTIVITY; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; BENZODIAZEPINES; GABA-A RECEPTOR AGONISTS; GABA-A RECEPTOR ANTAGONISTS; HUMANS; MODELS, NEUROLOGICAL; PROTEIN SUBUNITS; RECEPTORS, GABA-A;

EID: 84856905846     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11599020-000000000-00000     Document Type: Review

References (87)

1. Ng YT, Collins SD. Clobazam. Neurotherapeutics 2007; 4 (1): 138-44 (Pubitemid 46107321)
2. Wieck HH, Blaha L, Heerklotz B. A clinical view of clobazam. Br J Clin Pharmacol 1979; 7 Suppl. 1: 109S-112S (Pubitemid 9143914)
3. Gastaut H. Exceptional and unrecognized antiepileptic properties of a commercial anxiolytic: clobazam. Concours Med 1978; 100: 3697-701
4. Gastaut H, Low MD. Antiepileptic properties of clobazam, a 1-5 benzodiazepine, in man. Epilepsia 1979; 20 (4): 437-46 (Pubitemid 9208031)
5. Conry JA, Ng YT, Paolicchi JM, et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia 2009; 50 (5): 1158-66
6. Ng YT, Conry JA, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 2011; 77 (15): 1473-81
7. Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia 1998; 39 (9): 952-9
8. Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebocontrolled syndrome-dedicated trial. STICLO study group. Lancet 2000; 356 (9242): 1638-42
9. Lundbeck Inc. FDA approves ONFI-(clobazam) for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years and older [media release]. 2011 Oct 24 [online]. Available from URL: http://www.lundbeckinc.com/USA/media/press-releases/2011/11-October 24 [Accessed 2011 Nov 25]
10. American Hospital Formulary Service. AHFS drug information 2009. Bethesda (MD): American Society of Healthsystem Pharmacists, 2009
11. United Nations. Recommended methods for the detection and assay of barbiturates and benzodiazepines in biological specimens [online]. Available from URL: http://www. unodc.org/pdf/publications/report-detection-1997-01-01-1. pdf [Accessed 2011 Jun 15]
12. National Library of Medicine. Daily med current medication information [online]. Available from URL: http://dailymed. nlm.nih.gov/dailymed/about.cfm [Accessed 2011 Jun 16]
13. National Library of Medicine. Drug information portal [online]. Available from URL: http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp [Accessed 2011 Jun 15]
14. Kangas L, Breimer DD. Clinical pharmacokinetics of nitrazepam. Clin Pharmacokinet 1981; 6 (5): 346-66 (Pubitemid 12198388)
15. Shader RI, Greenblatt DJ. The use of benzodiazepines in clinical practice. Br J Clin Pharmacol 1981; 11 Suppl. 1: 5S-9S (Pubitemid 11151288)
16. Walzer M, Bekersky I, Blum R. Pharmacokinetic drug-drug interactions of clobazam. Pharmacotherapy. In press
17. Chouinard G. Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 2004; 65 Suppl. 5: 7-12
18. Barker MJ, Greenwood KM, Jackson M, et al. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004; 18 (1): 37-48 (Pubitemid 38197758)
19. Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry 2005; 66 Suppl. 2: 9-13 (Pubitemid 40343675)
20. Barzaghi F, Fournex R, Mantegazza P. Pharmacological and toxicological properties of clobazam(1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-diketo- 3H-1,5-benzodiazepine), a new psychotherapeutic agent. Arzneimittelforschung 1973; 23 (5): 683-6
21. Kuch H. Clobazam: chemical aspects of the 1,4 and 1,5-benzodiazepines. Br J Clin Pharmacol 1979; 7 Suppl. 1: 17S-21S (Pubitemid 9142683)
22. Rupp W, Badian M, Christ O, et al. Pharmacokinetics of single and multiple doses of clobazam in humans. Br J Clin Pharmacol 1979; 7 Suppl. 1: 51S-7S (Pubitemid 9154215)
23. Giraud C, Tran A, Rey E, et al. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos 2004; 32 (11): 1279-86 (Pubitemid 39410913)
24. Bun H, Monjanel-Mouterde S, Noel F, et al. Effects of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethylclobazam. Pharmacol Toxicol 1990; 67 (2): 136-40 (Pubitemid 20354494)
25. Kosaki K, Tamura K, Sato R, et al. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev 2004; 26 (8): 530-4 (Pubitemid 39463345)
26. Chapman AG, Horton RW, Meldrum BS. Anticonvulsant action of a 1,5-benzodiazepine, clobazam, in reflex epilepsy. Epilepsia 1978; 19 (3): 293-9 (Pubitemid 8367462)
27. Steru L, Chermat R, Millet B, et al. Comparative study in mice of ten 1,4-benzodiazepines and of clobazam: anticonvulsant, anxiolytic, sedative, and myorelaxant effects. Epilepsia 1986; 27 Suppl. 1: S14-7 (Pubitemid 16027709)
28. Shenoy AK, Miyahara JT, Swinyard EA, et al. Comparative anticonvulsant activity and neurotoxicity of clobazam, diazepam, phenobarbital, and valproate in mice and rats. Epilepsia 1982; 23 (4): 399-408 (Pubitemid 12007362)
29. Koeppen D. Review of clinical studies on clobazam. Br J Clin Pharmacol 1979; 7 Suppl. 1: 139S-50S (Pubitemid 9153294)
30. Borland RG, Nicholson AN. Immediate effects on human performance of a 1,5-benzodiazepine (clobazam) compared with the 1,4-benzodiazepines, chlordiazepoxide hydrochloride and diazepam. Br J Clin Pharmacol 1975; 2 (3): 215-21
31. Biehl B. Studies of clobazam and car-driving. Br J Clin Pharmacol 1979; 7 Suppl. 1: 85S-90S (Pubitemid 9154214)
32. Hindmarch I. Some aspects of the effects of clobazam on human psychomotor performance. Br J Clin Pharmacol 1979; 7 Suppl. 1: 77S-82S (Pubitemid 9143917)
33. Salkind MR, Hanks GW, Silverstone JT. Evaluation of the effects of clobazam, a 1,5 benzodiazepine, on mood and psychomotor performance in clinically anxious patients in general practice. Br J Clin Pharmacol 1979; 7 Suppl. 1: 113S-8S (Pubitemid 9153302)
34. Wittenborn JR, Flaherty Jr CF, McGough WE, et al. Psychomotor changes during initial day of benzodiazepine medication. Br J Clin Pharmacol 1979; 7 Suppl. 1: 69S-76S (Pubitemid 9145042)
35. Patat A, Klein MJ, Hucher M. Effects of single oral doses of clobazam, diazepam and lorazepam on performance tasks and memory. Eur J Clin Pharmacol 1987; 32 (5): 461-6 (Pubitemid 17096189)
36. Bourin M, Auget JL, Colombel MC, et al. Effects of single oral doses of bromazepam, buspirone and clobazam on performance tasks and memory. Neuropsychobiology 1989; 22 (3): 141-5 (Pubitemid 20291712)
37. Wildin JD, Pleuvry BJ, Mawer GE, et al. Respiratory and sedative effects of clobazam and clonazepam in volunteers. Br J Clin Pharmacol 1990; 29 (2): 169-77 (Pubitemid 20131414)
38. Tortora GJ, Derrickson B. Principles of anatomy and physiology. Hoboken (NJ): John Wiley & Sons, Inc., 2006
39. Benarroch EE. GABA receptor heterogeneity, function, and implications for epilepsy. Neurology 2007; 68: 612-14
40. Brickley SG, Cull-Candy SG, Farrant M. Development of a tonic form of synaptic inhibition in rat cerebellar granule cells resulting from persistent activation of GABAA receptors. J Physiol 1996; 497 (Pt 3): 753-9
41. Richerson GB. Looking for GABA in all the wrong places: the relevance of extrasynaptic GABA(A) receptors to epilepsy. Epilepsy Curr 2004; 4 (6): 239-42
42. Leonard BE.Areview of the pharmacological properties of the benzodiazepine anxiolytics. In: Trimble MR, Hindmarch I, editors. Benzodiazepines. Petersfield: Wrightson Biomedical Publishing Inc., 2000: 1-16
43. Haefely W, Martin JR, Schoch P. Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol Sci 1990; 11 (11): 452-6 (Pubitemid 20351930)
44. Costa E, Guidotti A. Benzodiazepines on trial: a research strategy for their rehabilitation. Trends Pharmacol Sci 1996; 17 (5): 192-200 (Pubitemid 26186205)
45. Atack JR. The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Expert Opin Investig Drugs 2005; 14 (5): 601-18 (Pubitemid 40790282)
46. Olsen RW, Sieghart W. International Union of Pharmacology: LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function-update. Pharmacol Rev 2008; 60 (3): 243-60
47. Smith GB, Olsen RW. Functional domains of GABAA receptors. Trends Pharmacol Sci 1995; 16 (5): 162-8
48. Sieghart W. Subunit composition and structure of GABA A-receptor subtypes. In: Enna S, editor. The GABA receptors. 3rd ed. Totowa (NJ): Humana Press Inc., 2007: 69-86
49. Sieghart W, Sperk G. Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr Top Med Chem 2002; 2 (8): 795-816
50. McKernan RM, Whiting PJ. Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci 1996; 19 (4): 139-43
51. Sigel E, Baur R, Boulineau N, et al. Impact of subunit positioning on GABAA receptor function. Biochem Soc Trans 2006; 34 (Pt 5): 868-71 (Pubitemid 44796440)
52. Mohler H. GABA(A) receptor diversity and pharmacology. Cell Tissue Res 2006; 326 (2): 505-16
53. Brickley SG, Revilla V, Cull-Candy SG, et al. Adaptive regulation of neuronal excitability by a voltage-independent potassium conductance. Nature 2001; 409 (6816): 88-92 (Pubitemid 32098630)
54. Richardson BD, Ling LL, Uteshev VV, et al. Extrasynaptic GABA(A) receptors and tonic inhibition in rat auditory thalamus. PLoS One 2011; 6 (1): e16508
55. Chandra D, Jia F, Liang J, et al. GABAA receptor alpha 4 subunits mediate extrasynaptic inhibition in thalamus and dentate gyrus and the action of gaboxadol. Proc Natl Acad Sci USA 2006; 103 (41): 15230-5 (Pubitemid 44583193)
56. Hevers W, Luddens H. The diversity of GABAA receptors: pharmacological and electrophysiological properties of GABAAchannel subtypes.Mol Neurobiol 1998; 18 (1): 35-86 (Pubitemid 28501074)
57. Costa E, Guidotti A, Mao CC. Evidence for involvement of GABA in the action of benzodiazepines: studies on rat cerebellum. Adv Biochem Psychopharmacol 1975; (14): 113-30
58. Haefely W, Kulcsar A, Mohler H, et al. Possible involvement of GABA in the central actions of benzodiazepines. Adv Biochem Psychopharmacol 1975; (14): 131-51
59. Braestrup C, Squires RF. Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H) diazepam binding. Proc Natl Acad Sci USA 1977; 74 (9): 3805-9 (Pubitemid 8189972)
60. Mohler H, Okada T. Benzodiazepine receptor: demonstration in the central nervous system. Science 1977; 198 (4319): 849-51 (Pubitemid 8214700)
61. Chang LR, Barnard EA, Lo MM, et al. Molecular sizes of benzodiazepine receptors and the interacting GABA receptors in the membrane are identical. FEBS Lett 1981; 126 (2): 309-12 (Pubitemid 11092806)
62. Olsen RW. GABA-benzodiazepine-barbiturate receptor interactions. J Neurochem 1981; 37 (1): 1-13 (Pubitemid 11088650)
63. Paul SM, Marangos PJ, Skolnick P. The benzodiazepine-GABA-chloride ionophore receptor complex: common site of minor tranquilizer action. Biol Psychiatry 1981; 16 (3): 213-29 (Pubitemid 11154875)
64. Sigel E, Barnard EA. A gamma-aminobutyric acid/benzodiazepine receptor complex from bovine cerebral cortex: improved purification with preservation of regulatory sites and their interactions. J Biol Chem1984; 259 (11): 7219-23 (Pubitemid 14077806)
65. Barnard EA, Skolnick P, Olsen RW, et al. International Union of Pharmacology: XV. Subtypes of gammaaminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev 1998; 50 (2): 291-313 (Pubitemid 28304030)
66. Sieghart W. Molecular basis of pharmacological heterogeneity of GABAA receptors. Cell Signal 1992; 4 (3): 231-7
67. Langer SZ, Arbilla S. Imidazopyridines as a tool for the characterization of benzodiazepine receptors: a proposal for a pharmacological classification as omega receptor subtypes. Pharmacol Biochem Behav 1988; 29 (4): 763-6 (Pubitemid 19260922)
68. Sieghart W. Pharmacology of benzodiazepine receptors: an update. J Psychiatry Neurosci 1994; 19 (1): 24-9 (Pubitemid 24066601)
69. Nakamura F, Suzuki S, Nishimura S, et al. Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture. Epilepsia 1996; 37 (8): 728-35 (Pubitemid 26276940)
70. NakajimaH.Apharmacological profile of clobazam (Mystan), a new antiepileptic drug [in Japanese]. Nippon Yakurigaku Zasshi 2001; 118 (2): 117-22 (Pubitemid 32734656)
71. Gatta E, Cupello A, Di Braccio M, et al. New 1,5-benzodiazepine compounds: activity at native GABA(A) receptors. Neuroscience 2010; 166 (3): 917-23
72. Wieland HA, Luddens H, Seeburg PH. A single histidine in GABAA receptors is essential for benzodiazepine agonist binding. J Biol Chem 1992; 267 (3): 1426-9
73. McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 2000; 3 (6): 587-92 (Pubitemid 30332078)
74. Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999; 401 (6755): 796-800
75. Low K, Crestani F, Keist R, et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000; 290 (5489): 131-4
76. Collinson N, Kuenzi FM, Jarolimek W, et al. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J Neurosci 2002; 22 (13): 5572-80 (Pubitemid 35386478)
77. Homanics GE,De Lorey TM, Firestone LL, et al.Mice devoid of gamma-aminobutyrate type A receptor beta3 subunit have epilepsy, cleft palate, and hypersensitive behavior. Proc Natl Acad Sci USA 1997; 94 (8): 4143-8 (Pubitemid 27180513)
78. DeLorey TM, Handforth A, Anagnostaras SG, et al. Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome. J Neurosci 1998; 18 (20): 8505-14 (Pubitemid 28465025)
79. Mohler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther 2002; 300 (1): 2-8 (Pubitemid 34028501)
80. Fisher JL. Interactions between modulators of the GABA(A) receptor: stiripentol and benzodiazepines. Eur J Pharmacol 2011; 654 (2): 160-5
81. SavicMM, Huang S, Furtmuller R, et al. AreGABAA receptors containing alpha5 subunits contributing to the sedative properties of benzodiazepine site agonists? Neuropsychopharmacology 2008; 33 (2): 332-9 (Pubitemid 350243345)
82. D'Hulst C, Atack JR, Kooy RF. The complexity of the GABAA receptor shapes unique pharmacological profiles. Drug Discov Today 2009; 14 (17-18): 866-75
83. Benson JA, Low K, Keist R, et al. Pharmacology of recombinant gamma-aminobutyric acidA receptors rendered diazepam-insensitive by point-mutated alpha-subunits. FEBS Lett 1998; 431 (3): 400-4 (Pubitemid 28352398)
84. Kleingoor C, Wieland HA, Korpi ER, et al. Current potentiation by diazepam but not GABA sensitivity is determined by a single histidine residue. Neuroreport 1993; 4 (2): 187-90 (Pubitemid 23080872)
85. Fradley RL, Guscott MR, Bull S, et al. Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands. J Psychopharmacol 2007; 21 (4): 384-91 (Pubitemid 47077297)
86. Bouwman BM, Suffczynski P, Midzyanovskaya IS, et al. The effects of vigabatrin on spike and wave discharges in WAG/Rij rats. Epilepsy Res 2007; 76 (1): 34-40 (Pubitemid 47238596)
87. Van Buggenhout G, Fryns JP. Angelman syndrome (AS, MIM 105830). Eur J Hum Genet 2009; 17 (11): 1367-73